Former Legend Biotech chief to lead newco builder K2 Therapeutics

12 August 2026

Ying Huang has been named chief executive of K2 Therapeutics, a Boston and Singapore-based biotech assembling a cancer pipeline through licensing rather than in-house discovery. The appointment comes less than three weeks after he left the top job at USA-based cell therapy firm Legend Biotech (Nasdaq: LEGN), where his resignation took effect on July 24 after seven years at the company.

K2 was founded in 2024 by Boston investment firm MPM BioImpact with $50 million in seed financing, and says its portfolio now runs to eight programs spanning antibody-drug conjugates and T-cell engagers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK